Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trumenba + nimenrix
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Trumenba + Nimenrix is a combination of two vaccines used for active immunization against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, B, C, W, and Y. **Trumenba** is a recombinant protein vaccine targeting group B, specifically using lipidated factor H binding protein (fHbp) to induce bactericidal antibodies. **Nimenrix** is a conjugate vaccine containing capsular polysaccharides from groups A, C, W-135, and Y conjugated to carrier proteins, which triggers a T-cell dependent immune response against those serogroups. This combination covers the major causes of meningococcal disease globally, conferring broad protection against all relevant serogroups.
- Other names
- trumenba meningococcal group B vaccinenimenrix meningococcal group A, C, W-135 and Y conjugate vaccine
02
Targets
Meningococcal capsular polysaccharide serogroup YCFH (Complement factor H)Neisseria meningitidis serogroup W-135 capsular polysaccharidefHbp (Factor H-binding protein)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Meningococcal capsular polysaccharide serogroup C
Beyond the preview
Go deeper on trumenba + nimenrix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trumenba + nimenrix.